Kalaris Therapeutics (KLRS) Misses Q1 EPS by 46c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q1 EPS of ($0.46).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• CrowdStrike shares jump on earnings beat, raised outlook
• Agilent Technologies (A) Tops Q3 EPS by 13c, Beats on Revenue; Offers FY EPS Guidance
• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance